Approval · Notice of Compliance 31916 · 2023
PRO-GABAPENTIN: Notice of Compliance 31916
Issued October 20, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31916
- Date
- October 20, 2023
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Labelling Update (to match Licensor)
- Canadian reference product
- NEURONTIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-GABAPENTIN | Not yet assigned | — |
Medicinal ingredients
- GABAPENTIN 600 MG per TAB
- GABAPENTIN 800 MG per TAB